LEFP
NBIX icon

Leading Edge Financial Planning’s Neurocrine Biosciences NBIX Stock Holding History

Leading Edge Financial Planning’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$218K Sell
1,294
-325
-20% -$48.2K 0.04% 72
2026
Q1 		$213K Buy
1,619
+2
+0.1% +$265 0.04% 71
2025
Q4 		$229K Buy
1,617
+2
+0.1% +$290 0.05% 59
2025
Q3 		$227K Buy
+1,615
New +$219K 0.06% 58

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Leading Edge Financial Planning's NBIX Position: Q2 2026 in Review

Leading Edge Financial Planning reduced its Neurocrine Biosciences (NBIX) stake by 20% in Q2 2026, selling an estimated $48.2K and leaving 1,294 shares worth $218K. The position accounts for 0.04% of the portfolio, ranked #72.

Leading Edge Financial Planning first reported a position in NBIX in Q3 2025 and has held it in 4 quarters since. The position peaked at $229K in Q4 2025. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Leading Edge Financial Planning held 1,294 shares of Neurocrine Biosciences worth $218K as of Q2 2026.
  • Leading Edge Financial Planning sold 325 Neurocrine Biosciences shares in Q2 2026, an estimated $48.2K.
  • Neurocrine Biosciences made up 0.04% of Leading Edge Financial Planning's portfolio in Q2 2026, its #72 holding.
  • Leading Edge Financial Planning first reported a position in Neurocrine Biosciences in Q3 2025 and has held it in 4 quarters since.
  • Leading Edge Financial Planning's Neurocrine Biosciences position peaked at $229K in Q4 2025.
  • 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Leading Edge Financial Planning's 13F filing for Q2 2026, filed 6 Aug 2026.